Genetic variation alone may not account for common chronic disease susceptibility. Rather, an interaction between genetic and environmental factors may clarify the underlying disease mechanism. Hence, we tested whether body mass index (BMI) modified the genetic association of the apolipoprotein E E4 allele with cognitive decline. The data came from a longitudinal population-based sample of 4055 participants interviewed at 3-year intervals from 1993 to 2012. Cognitive function was assessed using a standardized global cognitive score and BMI was assessed at baseline and classified as normal, overweight, and obese. There were 1374 (34%) participants with the E4 allele. In normal BMI participants, cognitive decline was 0.048 units/y without the E4 allele, and increased by an additional 0.031 units/y with the E4 allele. In overweight participants, cognitive decline was 0.038 units/y without the E4 allele, and increased by an additional 0.026 units/y with the E4 allele. Finally, in obese participants, cognitive decline was 0.038 units/y without the E4 allele, and increased by an additional 0.014 units/y with the E4 allele. The association of E4 allele with cognitive decline was significantly lower in obese participants compared with normal BMI participants (P = 0.003), thereby suggesting significant gene-environment interaction on cognitive decline.
(Alzheimer Dis Assoc Disord 2014; 28:134-140) C ognitive decline and Alzheimer disease (AD) are major causes of morbidity and mortality in older adults. [1] [2] [3] [4] As life expectancy increases, the risk of late-life AD and the associated health care burden concomitantly rises. Thus, it is imperative to identify risk factors associated with cognitive decline that may also alter the risk of late-life AD. Among such risk factors is the apolipoprotein E (APOE) E4 allele found on chromosome 19 that has been shown to be associated with an increased risk for cognitive decline, cognitive impairment, and late-life AD. [5] [6] [7] [8] [9] The APOE gene encodes a protein that helps carry cholesterol and other types of lipids in blood. Even though the molecular pathogenesis of APOE and late-life AD is not completely understood, it has been postulated that insufficient fat and cholesterol transported to the brain may reduce the clearance of b-amyloid from the brain, thereby increasing the risk of late-life AD. 10 In the general population, about 25% to 30% carry the APOE E4 allele, of whom only about 40% develop latelife AD, underscoring the nondeterministic nature of this genetic variation. 11 This suggests that genetic variation alone likely cannot account for late-life AD susceptibility without the inclusion of environmental factors. One such environmental factor that has been shown to have a differential association on cognitive decline, especially during late life, is body mass index (BMI). A lower level of BMI in older age has been shown to be associated with an increased risk of late-life AD. 12, 13 However, the association of low BMI with cognitive function and subsequent decline are also presumed to be markers of pathologic and neurological deterioration. In contrast, there is conflicting evidence for the association of higher BMI with cognitive function and subsequent decline. For example, Cournot et al 14 found that higher BMI was associated with lower baseline and decline in cognitive function measured by word-list learning in middle-aged men and women. Similarly, Yoon et al 15 showed that higher BMI was associated with lower cognitive function in a cross-sectional study of 250 subjects. However, Doruk et al 16 reported that being overweight or obese was associated with a lower risk of cognitive decline in a sample of older adults. In addition, Sturman et al 17 found that BMI was not associated with cognitive decline in a population-based sample. These differences in findings might be explained by the underlying interaction of the genetic lipid transport mechanism with metabolic syndrome in older adults. Therefore, one may postulate that cognitive decline may accelerate or slow, depending on significant APOE and BMI interaction in older age.
To better understand the underlying mechanism, we examined the interaction of APOE E4 allele status with BMI on cognitive decline in older adults, while controlling for stroke, hypertension, heart disease, and diabetes and demographic variables such as age, sex, education, and race. We examined these associations in our sample of 4055 participants who were followed for up to 18.7 years (average follow-up of 9.2 y). Hence, we tested the hypothesis that BMI modifies the association of the APOE E4 allele and cognitive decline in older adults.
METHODS

Participants
The Chicago Health and Aging Project (CHAP) is a longitudinal, population-based study of AD and other common health conditions among adults 65 years or older performed from 1993 to 2012. The CHAP study has been described in greater detail by Evans et al 18 and Bienias et al. 19 Briefly, baseline data were collected beginning in 1993, where about 79% of residents 65 years and older provided consent to participate in the study (original cohort). The CHAP study used a rolling enrollment scheme, where community residents who attained the age of 65 years were also enrolled as successive cohorts. Of the total of 10,802 subjects enrolled in CHAP, 6158 were enrolled as members of the original cohort and 4644 as members of successive cohorts.
Study participants who provided data for at least 2 cycles of data collection were included in this investigation. From the original CHAP study of 10,802 participants, we excluded subjects who died without a follow-up (2796), participants who declined follow-up participation (171), participants who completed 2 or more cognitive tests but had no DNA extracted (3594), participants who did not provide sufficient information for calculating cognitive test results (78), and participants who did not provide baseline BMI or covariate data (33). Thus, the study sample consisted of 4130 participants. However, our analysis removed 75 participants with low BMI, generally considered as a marker of end of life, resulting in a final analytical sample of 4055 participants.
Data Collection and Measures
BMI was collected at the baseline interview for the study participants. Cognitive function was collected at baseline and all subsequent follow-ups starting from cycle 1 through cycle 6, each 3 years apart, as part of the in-home population interview. Cognitive function was collected for 6 cycles for the original cohort and 2 to 5 cycles for successive cohorts. At the end of the cycle 2 population interview, DNA samples were collected from a stratified random sample of the population, about one sixth of all participants. Toward the end of cycle 5 and for the entire cycle 6, DNA samples were collected from all subjects during their population interviews. Thus, APOE genotype was ascertained through a combination of stratified random sample and population sample of participants from the original and successive cohorts.
As a sample description problem, we compared those who died without providing a follow-up interview to those who provided 2 or more follow-up interviews, and found that those who died had significantly lower cognitive function at baseline assessment (P < 0.0001). BMI was also significantly lower in participants who had died compared with those who provided 2 or more cognitive function data (P < 0.0001). We also compared those who completed 2 or more cognitive function tests without DNA samples to those with 2 or more cognitive tests with DNA samples. We found that those who provided DNA samples had a significantly higher cognitive function (P < 0.0001) and showed slower cognitive decline (P < 0.0001) compared with those who were not chosen for DNA extraction. However, the patterns of cognitive decline in normal, overweight, and obese participants were similar between those included and excluded from the analysis.
Cognitive Function
Cognitive function was evaluated using a battery of 4 tests including 2 tests of episodic memory (immediate and delayed recall) derived from the East Boston Test, 20,21 a test of perceptual speed (the Symbol Digits Modalities Test), 22 and a test of general orientation and global cognition (the Mini-Mental State Examination). 23 Because tests loaded on a single factor that accounted for about 75% of the variance in a factor analysis, 24 we constructed a composite measure of global cognitive function based on all 4 tests. This measure combines variables with different ranges and floor-ceiling effects by averaging the 4 tests together after centering and scaling each to their baseline mean and SD. Thus, a participant whose composite performance matches the average participant at baseline has a composite cognitive score of 0, and a person who performs 1 SD better than average on every test has a composite cognitive score of + 1. To provide some prospective of our global composite score, participants with a positive diagnosis of AD in our sample had an average cognitive function of À0.579 SD units at the population interview (using NINCDS-ADRDA criteria). 25 The diagnosis of AD and mild cognitive impairment was performed at the end of cycle 2; hence, a diagnosis for AD or mild cognitive impairment was unknown at baseline. However, in a sensitivity analysis, we removed participants below the fifth, 10th, and 15th percentile of baseline cognitive function from our analysis.
BMI
BMI was assessed at baseline during the in-home interview by measuring the participants' weight in pounds and asking about height, measured in feet and inches, by the question: "What is your height?" All measurements were converted to the standard metric system for weight to kilograms and height to meters. Then, BMI was computed as kg/m 2 and categorized as underweight (< 18.5 kg/m 2 ), normal (18.5 to <25 kg/m 2 ), overweight (25 to <30 kg/m 2 ), and obese (Z30 kg/m 2 ), based on the classification by the World Health Organization (WHO). 26 We created indicator variables for overweight and obesity with normal as the reference group, as prior literature suggests a U-shaped or J-shaped relationship between BMI and cognitive decline. We performed a descriptive analysis on 75 underweight participants, but removed them from our analysis, as these participants were significantly older with poor health conditions, and more importantly, about 47% of them were diagnosed with AD.
APOE Allele
APOE genotyping was done using the methods described by Hixson and Vernier 27 based on the primers described by Wenham et al. 28 APOE E4 genotypes were determined using 2 single nucleotide polymorphisms (SNPs): rs7412 and rs429358. These SNPs were genotyped in each subject using the hME Sequenom MassARRAY platform. The genotyping success rate was 100% for SNP rs7412 and 99.8% for SNP rs429358. Both SNPs were in Hardy-Weinberg equilibrium with P-values of 0.0833 and 0.7925, respectively. APOE isoforms for E2E2, E2E3, E2E4, E3E3, E3E4, and E4E4 were created based on these 2 SNPs. An indicator variable was created for participants who had 1 or more E4 allele.
The Institutional Review Board of Rush University Medical Center approved the study and all participants provided written, informed consent.
Covariates
Our analyses adjusted for age, sex, race (blacks vs. whites), and education (measured in number of years of schooling completed), and time-varying measures of 4 chronic health conditions that might mitigate the association of BMI and APOE E4 on cognitive decline: heart disease (heart attack or coronary thrombosis or coronary occlusion or myocardial infarction), hypertension, stroke, and diabetes.
Statistical Analysis
Descriptive statistics were computed using weighted sample means and SDs for continuous variables and percentages for categorical variables stratified by BMI groups after adjusting for sample weights (design-based adjustment). In our sample of underweight participants, higher levels of neurodegenerative disease and chronic health conditions were observed, and hence, removed from our descriptive tests and regression models. To better understand the interaction of BMI and APOE on cognitive function, we also performed a descriptive analysis of blood biomarkers stratified by BMI groups. We compared baseline characteristics using an analysis of variance F tests for continuous measures and a w 2 test statistic for categorical measures.
In terms of modeling, we used weighted linear mixedeffects regression model to examine cognitive decline stratified by BMI subgroups. 29 From our regression models, we estimated coefficients of interest and their associated variances using linear contrasts. We tested cognitive decline between the normal and overweight participants, and normal and obese participants, using 2 additional models with a 3-way interaction of overweight and obese indicators with time and APOE E4 allele status. In a separate analysis, we tested whether the association of APOE E4 allele and cognitive decline in normal, overweight, and obese participants was different between non-Hispanic blacks and whites. For this analysis, we used 3-way interactions of APOE, BMI categories, and time for each of the ethnic groups. We used 4-way interactions of indicator for race/ethnicity, APOE BMI categories, and time to test whether the association of BMI categories, APOE, and time with cognitive decline was different between blacks and whites.
Our estimation process was complicated by mixed sampling scheme of stratified and population samples. Of the 4055 included in our regression model, 2198 were selected using a stratified random sample from the population, and the remaining 1857 were part of the population sample. To account for this sampling structure, we computed subject-specific sample weights for participants from the stratified random sample, while setting those from the population to be equal to 1. Given that sample weights were design features, the parameter estimates from a weighted regression model would be unbiased for this sampling scheme, but the variance estimates may be biased. To remedy this situation, we estimated bootstrap sampling weights for a mixture of 2-stage sampling and population sampling schemes. 30, 31 We estimated variances for parameter estimates in the BMI-specific and combined models using this resampling procedure. All models were fitted using R version 2.15.3 using the lmer function in the lme4 package, and bootstrap variances were estimated with coding program using the sampling package. 32 
RESULTS
The study sample consisted of 4130 (70% blacks and 63% females) participants with a genotyped APOE allele and BMI data and 2 or more cognitive function measurements. Of the 4130 participants, 75 (2%) reported underweight, 1091 (26%) reported normal, 1531 (37%) reported overweight, and 1433 (35%) reported obese BMI levels. The demographic and health characteristics of the sample are shown in Table 1 . Underweight participants had significant adverse health conditions including diagnosis of AD and subsequently were removed from our analysis. Of the remaining 4055 participants, about 34% of the participants had at least 1 APOE E4 allele and the percentage of participants with APOE E4 allele was not significantly different across the BMI groups (P = 0.07). At baseline, global cognitive function, mini-mental state examination, symbol digits tests, and delayed and immediate recall tests were not significantly different between the 3 BMI groups (P > 0.05). Obese participants were mostly younger black females with higher rates of hypertension and diabetes and a lower prevalence of diagnosed AD. From Table 2 , age, sex, race, and education were associated with baseline cognitive function. Older age was associated with lower levels of cognition and faster cognitive decline over the duration of follow-up. In addition, normal BMI participants with the APOE E4 allele had significantly lower baseline levels of cognitive function compared with those with no E4 allele. However, no such baseline association was observed in overweight and obese participants.
In terms of cognitive decline over time, cognitive function declined by 0.048 units/y (SE = 0.003; P < 0.0001) among normal BMI participants without the APOE E4 allele. Cognitive decline increased by an additional 0.031 units/y (SE = 0.005; P < 0.0001) in normal BMI participants with the APOE E4 allele. Using a linear contrast, participants with normal BMI and the APOE E4 allele had a cognitive decline of 0.079 units/y (adding 0.048 and 0.031; SE = 0.005). In an effort to provide a better interpretation of these cognitive decline effects, we estimated the number of hypothetical years of cognitive decline that equates to average cognitive function among those with incident AD diagnosis in our sample. Using our regression estimates, normal BMI participants without the APOE E4 allele would hypothetically have 9.8 years to reach average cognitive function similar to participants diagnosed with AD, and 5.9 years for normal BMI participants with the APOE E4 allele.
Cognitive function declined by 0.038 units/y (SE = 0.002; P < 0.0001) for overweight participants without the APOE E4 allele. Cognitive decline increased by an additional 0.026 units/y (SE = 0.003; P < 0.0001) in overweight participants with the APOE E4 allele. Using a linear contrast, cognitive function declined by 0.064 units/y (adding 0.038 and 0.025; SE = 0.003) in overweight participants with the APOE E4 allele. Using a combined model, cognitive decline was slower by 0.010 units/y (SE = 0.004; P = 0.021; data not shown) among overweight participants without the APOE E4 allele and 0.016 units/y (SE = 0.005; P = 0.004; data not shown) among overweight participants with the APOE E4 allele compared with normal BMI participants. Even though cognitive decline in overweight participants was slower than normal participants, we did not find a significant difference in the association of the APOE E4 allele between normal and overweight participants (P = 0.27; data not shown). On an average, overweight participants without the APOE E4 allele would hypothetically have 16.8 years to reach average cognitive function similar to participants diagnosed with AD, and 8.8 years for overweight participants with the APOE E4 allele.
In obese BMI participants, cognitive function declined by 0.038 units/y (SE = 0.003; P < 0.0001) among those without the APOE E4 allele, which increased by 0.014 units/ y (SE = 0.003; P < 0.0001) among those with the APOE E4 allele. Using a linear contrast, obese participants with the APOE E4 allele had cognitive decline of 0.052 units/y (adding 0.038 and 0.014; SE = 0.003). Using a combined model for normal and obese participants, cognitive decline in obese participants was significantly slower by 0.010 units/y (SE = 0.005; P = 0.031; data not shown) among participants without the APOE E4 allele and 0.025 units/y (SE = 0.005; P < 0.0001; data not shown) among obese participants with the APOE E4 allele compared with normal BMI participants. In addition, the association of the APOE E4 allele was significantly different between normal and overweight participants (P = 0.003; data not shown). Hypothetically, obese BMI participants without the APOE E4 allele would have 15.1 years to reach average cognitive function similar to participants diagnosed with AD, and 10.8 years for obese participants with the APOE E4 allele.
To illustrate these associations, we computed cognitive decline estimates for BMI groups among those without and with the APOE E4 allele. Figure 1A compares the trajectories of normal and overweight BMI participants. The decline in normal participants without the APOE E4 allele (solid line) was faster than overweight participants without the APOE E4 allele (dotted line). In addition, cognitive function in overweight participants with the APOE E4 allele (dotted and dashed line) was significantly slower than normal BMI participants with the APOE E4 allele (dashed line). Figure 1B compares obese participants to normal BMI participants. Cognitive decline in obese participants with (dotted and dashed line) was slower than normal participants without (solid line) and with (dashed line) the APOE E4 allele.
As a secondary analysis, we wanted to examine whether the presence of the APOE E4 allele has a dose response to cognitive decline in obese participants. Hence, we compared cognitive decline among obese participants with no copy of the E4 allele to 1 copy of the E4 allele and 2 copies of the E4 alleles. Cognitive function declined by 0.036 units/y among those with no copy of the E4 allele, 0.049 units/y among those with 1 copy of the APOE E4 allele, and 0.057 units/y among those with 2 copies of the E4 allele. The rate of cognitive decline from 0 to 1 copy of the APOE E4 allele was significant (P < 0.0001; data not shown), but the change from 1 to 2 copies was not significant (P = 0.54; data not shown), suggesting no dose response increase in risk of cognitive decline in obese participants. *Models were also adjusted for stroke, myocardial infarction, hypertension and diabetes. 1 As a sensitivity analysis, we removed participants in the lowest fifth, 10th, and 15th percentile of baseline cognitive function from our analyses. From those models, cognitive decline ranged from 0. This sensitivity analysis showed that the association of the APOE E4 allele with cognitive decline in the BMI subgroups was robust and largely unchanged after removing participants in the lowest percentiles of baseline cognitive function. In another sensitivity analysis, we estimated the association of APOE and BMI categories on cognitive decline while accounting for selection bias due to mortality. We found that our estimates of cognitive decline in normal BMI participants with and without APOE E4 allele was somewhat higher in our mortality adjusted model compared with core models presented in Table 2 . However, the estimates in the overweight and obese groups were mostly unchanged, thereby providing further evidence for robustness of our findings, and reducing the possibility of selection bias impacting our findings.
In a separate analysis, we tested whether BMI also modified the association of the APOE E4 allele with cognitive decline differently between blacks and whites ( Table 3 ). In normal BMI participants, cognitive decline was 0.044 units/y in black participants without the APOE E4 allele, and increased by 0.031 units/y among those with the APOE E4 allele. Among overweight and obese black participants without the APOE E4 allele, BMI was not associated with an increase in cognitive decline relative to normal BMI participants. However, using a linear contrast, overweight and obese black participants with the APOE E4 allele showed significantly slower change in cognitive decline by 0.012 and 0.016 units/y, respectively. In white participants with normal BMI, cognitive decline was 0.052 units/y among those without the APOE E4 allele and increased by 0.040 units/y among those with the APOE E4 allele. Among overweight and obese white participants without the APOE E4 allele, BMI was not associated with increased cognitive decline. Using a linear contrast, overweight and obese white participants showed significantly slower increase in cognitive decline by 0.017 and 0.027 units/y, respectively. Using a combined model, blacks and whites did not show a significantly different increase in cognitive functions overweight (P = 0.68; data not shown) and obese participants (P = 0.17; data not shown).
DISCUSSION
Cognitive decline in older age was differentially associated with BMI and APOE E4 allele status. The association of the APOE E4 allele with cognitive decline was lower in obese participants compared with normal BMI participants. In addition, cognitive decline in obese participants with the APOE E4 allele was not significantly different from normal BMI participants without the APOE E4 allele. We also did not find a significant difference in the association of BMI and APOE E4 allele in blacks and whites.
Our results contradict some of the earlier findings on the association of higher BMI and faster cognitive decline. The reasons for such disparate findings may be because of the differences in the following: the cognitive testing instruments used; the measurement of BMI discrete versus continuous; adjustment for important confounding variables; cross-sectional versus longitudinal designs, and smaller sample sizes. In these analyses, we controlled for important demographic and health variables from a well-designed longitudinal study with validated measures of cognitive testing in older adults. We used a priori BMI categorization based on the WHO recommendation rather than a continuous BMI measure which has the potential to show a nonlinear relationship with BMI as evidenced by prior studies.
The results of this study provide some evidence for gene-environment interaction models. Specifically, the association of cognitive decline with genetic risk factors, such as APOE may significantly vary by BMI classifications, providing evidence for reduced genetic risk of the APOE E4 allele among subgroups of participants. The findings from this study also suggest that the direct association of obesity through the dysfunction in the lipid transport mechanism on cognitive function is not as high among obese participants. However, there may be indirect associations that may increase the risk of cognitive decline in obese participants through other pathways that have not been investigated here. Nonetheless, we observed a positive association between participants with obese BMI and cognitive decline. As obesity is known to increase the risk of diabetes, heart disease, hypertension, and stroke, which also independently increase the risk of cognitive decline in older adults, we adjusted for several time-dependent chronic health conditions, such as, stroke, heart disease, hypertension, and diabetes. An analysis not adjusting for chronic health conditions provided slightly large cognitive declines, but obese participants still showed significantly slower decline than normal BMI participants. In an attempt to see if slower cognitive decline in obese participants extrapolated to lower risk of AD, we found that age, sex, and race-adjusted cognitive decline may help slow diagnosis of AD by about 5 years in those with APOE E4 allele.
The primary strength of this study is that it is one of the few large population-based studies with relevant data that has the requisite power to detect longitudinal change in cognitive function based on genetic and environmental risk factors. Our cognitive function tests were conducted every 3 years using the same instrument, providing a reliable estimate of long-term cognitive decline. Our analytical strategy accounted for complex sampling schemes, providing unbiased parameter estimates and their variances. We also adjusted for several demographic and chronic health conditions that may impact the association between BMI and cognitive function. Furthermore, our population comprised a large number of blacks from a population-based sample, and our secondary analysis suggested no significant difference in the association of the APOE E4 allele with AD between blacks and whites in any of the 3 BMI groups.
There are limitations to be noted. First, we used a 3-group classification of BMI that may not be most appropriate in a biological sense. Even though these BMI classifications were based on the WHO recommendations, BMI may be classified in other ways, such as N-point datadriven cutoffs that might provide a different relationship. However, using data-driven cutoffs might be harder to interpret, and might be driven by both empirical evidence and unknown latent factors, rendering the results harder to interpret. Second, we had a small number of underweight participants who were excluded from our analyses because they had a higher number of chronic health conditions. We found that the underweight participants had the fastest cognitive decline consistent with prior literature demonstrating poorer neurological functions and adverse health outcomes. Third, DNA samples were collected in about 40% of participants from the population-based sample that could give rise to selective attrition, especially among participants with higher levels of BMI; however, we did not find any significant differential attrition in the BMI groups for cognitive decline.
Even though our analyses were age, race, and sex adjusted, younger black participants might have slower decline than the rest of the population. However, our secondary analysis suggested no significant differences in the association of the APOE E4 allele and cognitive decline between blacks and whites, especially in the obese BMI group. It is also possible that this race effect might be explained by some other unobserved or unadjusted variable that has high correlation with BMI and needs to be further investigated.
We expect that our study serves 3 purposes: (1) to understand the APOE mechanism from the perspective of metabolic activity in late life, (2) to provide evidence for important gene-environment interactions that may be replicated in other large population-based studies, and (3) to provide direction for future intervention studies to address the genetic factors of obese participants in an attempt to reduce cognitive decline in older age.
In conclusion, we found that BMI was associated with cognitive decline among those with and without the APOE E4 allele; that is, the APOE E4 allele behaves differently in substrates of BMI. Specifically, we observed that obese participants with the APOE E4 allele had a slower cognitive decline than normal BMI participants with the APOE E4 allele. Despite the potential moderating association of obesity on slowing cognitive decline, one has to evaluate the deleterious effect of the obesity on other health-related problems in older age before making any public health recommendations. However, our study has shown significant gene-environment interplay with the risk of cognitive decline in a subgroup of APOE E4 allele carriers.
